Record Pharma Lobbying Spikes While Eli Lilly Halts India Obesity Ads

Summary

Behind the scenes of new drug pricing policies, the pharmaceutical industry has been spending record amounts to influence federal lawmakers. In 2025, the broader pharmaceutical and health products industry spent an unprecedented $457.3 million on lobbying. A significant chunk of this came from just 17 companies anchoring the TrumpRx prescription program. These specific companies poured more than $130 million into federal lobbying efforts, representing a massive 23 percent increase that easily outpaced the rest of the industry. This trend shows no signs of slowing down, with early 2026 reports already indicating a 5.7 percent year-over-year increase.

Meanwhile, pharmaceutical giant Eli Lilly has hit a regulatory roadblock in India. The company recently paused an obesity awareness campaign called "We Know Now" out of an abundance of caution. This decision came after the Drugs Controller General of India, the country's main regulatory authority for medicines, issued an advisory. The regulator cautioned that the campaign might violate strict national rules that prohibit the direct or indirect advertising of prescription medications, such as Eli Lilly's drug Mounjaro, to everyday consumers.

It is important to keep in mind that these updates are based on financial tracking and regulatory developments, not clinical science. The lobbying figures come from the campaign finance tracking group OpenSecrets, while the Eli Lilly developments are based on news reports from Reuters. This means these findings reflect market trends rather than peer-reviewed medical data.

Why it matters.

These developments highlight the immense financial power and complex regulatory hurdles shaping the modern pharmaceutical landscape. The record-breaking $457.3 million spent on lobbying in a single year underscores how much the industry is willing to invest to shape federal policies like the TrumpRx program. For patients and taxpayers, this massive financial influence raises important questions about how drug prices are negotiated and who ultimately benefits from new healthcare regulations.

On the global stage, Eli Lilly's halted campaign in India reveals the delicate line drugmakers must walk when discussing major health issues like obesity. While companies want to raise awareness for profitable treatments, they must navigate strict international advertising laws designed to protect consumers. As prescription weight-loss treatments continue to grow in popularity worldwide, we can expect to see more friction between corporate marketing efforts and national health regulators.

From the source

The story in numbers.

2025 federal lobbying spend by 17 TrumpRx companies: $130 million
Record industry-wide lobbying spend in 2025: $457.3 million
Surge in TrumpRx company lobbying in 2025: 23%

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Record Pharma Lobbying Spikes While Eli Lilly Halts India Obesity Ads

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.